Post-Rebif, Merck KGaA Keeps Faith With MS Therapies
CEO Stefan Oschmann is sticking to his previous forecast of annual peak sales of €500-700m for Mavenclad, excluding the US, and Merck has high hopes for another MS treatment, the BTK inhibitor evobrutinib, following promising Phase IIb data.
You may also be interested in...
The German group has been laying out its future plans to investors, which include reducing debt and a strong revenue stream from its Pfizer-partnered checkpoint inhibitor Bavencio.
The German group's oral treatment is late coming to the market but a key opinion leader believes that it will change the way multiple sclerosis is treated.
Vifor CEO Stefan Schulze tells Scrip that an expanded deal with Korsuva developer Cara Therapeutics means the US biotech will not have to invest in a commercial organization as the Swiss firm will mobilize its well-established sales force to launch the treatment for dialysis patients with CKD-associated pruritus.